



REINSURANCE HOT NEWS

October 1st, 2020

Several drugs are being added to the High Cost Specialty Drug BIO case type. The process for Reinsurance for these drugs will be the same as for other Biological/High Cost Specialty Drugs – please refer to the Reinsurance Manual for details.

Tecartus will also be added to the Specialty Contract, as soon as contracts are established. The reinsurance for this drug will be similar to Kymriah and Yescarta.

The effective date for the addition of all drugs listed below is October 1, 2020.

<i>FDA Approved Indication</i>	<i>Brand Name</i>	<i>Generic Name</i>	<i>Reinsurance Type</i>
Cystic Fibrosis	Orkambi	Lumacaftor/Ivacaftor	High Cost Specialty
Cystic Fibrosis	Symdeko	Tezacaftor/Ivacaftor	High Cost Specialty
Cystic Fibrosis	Trikafta	Elexacaftor, Tezacaftor & Ivacaftor	High Cost Specialty
Hereditary Angioedema	Ruconest	C1 Esterase Inhibitor	High Cost Specialty
Mantle Cell Lymphoma	Tecartus	Brexucabtagene Autoleucel	Specialty Contract
Spinal Muscular Atrophy	Evrysdi	Risdiplam	High Cost Specialty